Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/1b study of PUR-3100

Next Previous
X
Search
Trial Profile

Phase 1/1b study of PUR-3100

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dihydroergotamine mesilate (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors Pulmatrix

    • Most Recent Events

    • 29 Mar 2022 According to a Pulmatrix media release, This study will form the basis for a US IND.
    • 29 Mar 2022 According to a Pulmatrix media release, the company anticipates initiating patient dosing Australia in Q3 2022, with top-line data anticipated in Q4 2022.
    • 10 Nov 2021 According to a Pulmatrix media release, the company expects to submit the IND in Q1 2022 and initiate the Phase 1 study in Q2 2022 with top line data expected in Q3 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top